Next-gen Cell Therapies and Precision Immunotherapies are Driving Growth and New Product Development
Immuno-oncology (I-O) therapies target tumors by harnessing the host’s immune system. With the growing incidence and prevalence of various types of aggressive and refractory cancers, the next-generation I-O therapy pipeline has witnessed significant growth. Chimeric antigen receptor (CAR)-T cell therapy and tumor-targeted antibody therapies, including monoclonals, antibody-drug conjugates (ADCs), bispecific antibodies, and several therapeutic cancer vaccines, are making rapid strides in clinical trials as effective immunotherapy. This study discusses the key trends and technologies driving the development of such I-O therapies. It delves into advancements in cancer vaccines and cell therapies for various cancer indications, highlighting some of the innovators in this space. Next-generation cell therapies, personalized cancer vaccines, and strategic areas of focus have also been discussed in this report. The study examines the factors driving and restraining this industry and identifies the growth opportunities emerging from the changes in this space for market players and stakeholders to leverage.
Key questions answered in this study:
- What does the current clinical landscape of I-O therapies look like?
- Which are the technology enablers driving the adoption of I-O therapies?
- What are the key developments in adoptive cell therapies and cancer vaccines?
- What are the roadblocks to successful translation?
- What are the research and development (R&D) focus areas?
- What are the key focus areas for the future?
